<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133949</url>
  </required_header>
  <id_info>
    <org_study_id>PHRCIR09-DR-SCHMIDT</org_study_id>
    <nct_id>NCT03133949</nct_id>
  </id_info>
  <brief_title>Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria</brief_title>
  <official_title>Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory aortitis probably represents a heterogeneous group, and the clinical experience&#xD;
      accumulated over the last ten years, shared by the experts of the subject, is that the&#xD;
      initial clinical, biological or radiological characteristics should make it possible to&#xD;
      differentiate them and dismember the Nosological field.&#xD;
&#xD;
      This will be an essential first step before studying prognosis, risk factors, and therapeutic&#xD;
      options.&#xD;
&#xD;
      The search for diagnostic criteria on a large series, similar to the study of classification&#xD;
      of vascularites of the ACR in 1990, should make it possible to homogenize the diagnoses for&#xD;
      the different teams working on the subject, and to begin work Collaborations, which alone can&#xD;
      improve patient care in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 8, 2010</start_date>
  <completion_date type="Anticipated">July 8, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 8, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analyze the management of patients with aortic and retroperitoneal fibrosis</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">206</enrollment>
  <condition>Idiopathic Aortitis</condition>
  <condition>Retroperitoneal Fibrosis</condition>
  <arm_group>
    <arm_group_label>Patients with idiopathic inflammatory aortitis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>a group of witnesses</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Establish the clinical, biological and radiological characteristics of patients</intervention_name>
    <description>Establish the clinical, biological and radiological characteristics of patients</description>
    <arm_group_label>Patients with idiopathic inflammatory aortitis</arm_group_label>
    <arm_group_label>a group of witnesses</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with idiopathic inflammatory aortitis or retroperitoneal fibrosis.&#xD;
&#xD;
        Three focus groups will be constituted:&#xD;
&#xD;
        Group 1: it will include all cases of non-idiopathic inflammatory aortitis followed in the&#xD;
        participating centers over the last 15 years, Group 2: it will include patients with&#xD;
        non-inflammatory aortic conditions (aneurysm, atheroma, annulo-ectasitic aortic disease).&#xD;
&#xD;
        Group 3: it will include patients without aortic pathology matched by age and sex, having a&#xD;
        thoracoabdominal scanner or MRI in the participating centers.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cases :&#xD;
&#xD;
               -  All cases of idiopathic aortitis and retroperitoneal fibrosis followed in&#xD;
                  participating centers over the past 15 years will be collected.&#xD;
&#xD;
          -  Witnesses :&#xD;
&#xD;
               -  Group 1: non-idiopathic inflammatory aortitis: all cases of inflammatory aortitis&#xD;
                  (apart from idiopathic aortites and isolated retroperitoneal fibrosis) followed&#xD;
                  in the participating centers over the last 15 years will be collected.&#xD;
&#xD;
               -  Group 2: subjects with noninflammatory aortic disease, atheromatous type or&#xD;
                  annulo-ectasitic disease, matched by age and sex with cases. This group will be&#xD;
                  used to define the differential characteristics between idiopathic aortitis and&#xD;
                  noninflammatory aortic pathology.&#xD;
&#xD;
               -  Group 3: This group will include control subjects aimed at defining radiological&#xD;
                  normality criteria according to age and sex. As the images are machine-dependent,&#xD;
                  group 3 controls will be randomly selected from the radiology departments that&#xD;
                  have performed the scanner or MRI of the corresponding control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under 18 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean SCHMIDT, PhD</last_name>
    <phone>+33322668230</phone>
    <email>schmidt.jean@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean SCHMIDT, PhD</last_name>
      <phone>+33322668230</phone>
      <email>schmidt.jean@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortitis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Retroperitoneal Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

